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Abstract 
Background: Malaria in Yemen is mainly caused by Plasmodium falciparum and 25 % of the population is at high risk. 
Sulfadoxine–pyrimethamine (SP) had been used as monotherapy against P. falciparum. Emergence of chloroquine 
resistance led to the shift in anti-malarial treatment policy in Yemen to artemisinin-based combination therapy, that 
is artesunate (AS) plus SP as first-line therapy for uncomplicated malaria and artemether–lumefantrine as second-line 
treatment. This study aimed to screen mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthetase 
(dhps) genes associated with SP resistance among P. falciparum population in Hadhramout governorate, Yemen.
Methods: Genomic DNA was extracted from dried blood spots of 137 P. falciparum isolates collected from a com-
munity-based study. DNA was amplified using nested polymerase chain reaction (PCR) and subsequently sequenced 
for Pfdhfr and Pfdhps genes. Sequences were analysed for mutations in Pfdhfr gene codons 51, 59, 108, and 164 and in 
Pfdhps gene codons 436, 437, and 540.
Results: A total of 128 and 114 P. falciparum isolates were successfully sequenced for Pfdhfr and Pfdhps genes, 
respectively. Each Pfdhfr mutant allele (I51 and N108) in P. falciparum population had a frequency of 84 %. Pfdhfr R59 
mutant allele was detected in one isolate. Mutation at codon 437 (G437) in the Pfdhps gene was detected in 44.7 % 
of falciparum malaria isolates. Frequencies of Pfdhfr double mutant genotype (I51C59N108I164) and Pfdhfr/Pfdhps triple 
mutant genotype (I51C59N108I164-S436G437K540) were 82.8 and 39.3 %, respectively. One isolate harboured Pfdhfr triple 
mutant genotype (I51, R59, N108, I164) and Pfdhfr/Pfdhps quadruple mutant genotype (I51R59N108I164-S436G437K540).
Conclusion: High frequencies of Pfdhfr and Pfdhps mutant alleles and genotypes in P. falciparum population in 
Hadhramout, Yemen, highlight the risk of developing resistance for SP, the partner drug of AS, which subsequently 
will expose the parasite to AS monotherapy increasing then the potential of the emergence of AS resistance. Study 
findings necessitate the continuous monitoring of the efficacy of the national anti-malarial drugs policy in Yemen. In 
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Background
Malaria is a major health problem in Yemen, where more 
than 25  % of the population are at considerably high 
risk of malaria with 149,451 confirmed cases in 2013 
[1]. Malaria in Yemen belongs to the afro-tropical type 
with the predominance of Plasmodium falciparum and 
Anopheles arabiensis as the predominant vector. How-
ever, malaria epidemiology in Socotra Island and the 
eastern governorate of Al-Maharah belongs to the orien-
tal type with Anopheles culicifacies as the predominant 
vector [2, 3]. The National Malaria Control Programme 
(NMCP) in Yemen is proactive in controlling malaria 
through prompt diagnosis and proper treatment, dis-
tribution of insecticide-treated mosquito nets, indoor 
residual spraying, and active case surveillance [4].
The national anti-malarial drug policy in Yemen was 
formulated in 1999, including chloroquine (CQ) as first-
line and sulfadoxine–pyrimethamine (SP) as a second 
line monotherapy for treating uncomplicated falcipa-
rum malaria [5]. In 2005, due to the increased CQ resist-
ance, anti-malarial drug policy shifted to a combination 
of artesunate (AS) and SP as the first-line therapy and 
artemether–lumefantrine as a second-line treatment for 
uncomplicated malaria [6]. Continued use of SP in the 
new policy, availability of this drug in the private sector, 
and poor knowledge of the national policy among physi-
cians [7] may increase the monotherapy of SP against P. 
falciparum, which is likely to compromise drug efficacy. 
Monitoring anti-malarial drug efficacy in Yemen started 
in 2002 following the WHO protocol for in vivo assess-
ment in four sentinel sites. In 2004, three in vivo studies 
on the efficacy of SP showed success rate ranging from 95 
to 100 %. Four years later, after launching the new policy, 
in vivo efficacy trails conducted in three monitoring sites 
reported 97.6–100 % adequate clinical and parasitologi-
cal response (ACPR) for AS  +  SP [3]. The efficacity of 
AS + SP as first-line treatment for uncomplicated falci-
parum malaria was also rated at 97 % ACPR in a recent 
clinical drug efficacy trail carried out in 2013 [8]. It is 
noteworthy that currently used routine clinical efficacy 
trail is the gold standard for the assessment of the effi-
ciency of the combined anti-malarial drugs, although it 
does not differentiate between the efficacy of AS and its 
partner drug.
Molecular markers are practical for monitoring SP 
resistance. Quintuple mutant of combined dihydrofolate 
reductase (dhfr) and dihydropteroate synthase (dhps) 
genes (Pfdhfr I51, R59, N108 plus Pfdhps G437, E540) was 
significantly associated with in vivo resistance to SP [9]. 
In Yemen, mutant allele R59 of pfdhfr was detected in 
5 % of P. falciparum isolates (5/99) in Lahj governorate, 
southern Yemen [10]. Double mutant genotype of pfdhfr 
(I51/N108) was reported in 54 % of P. falciparum isolates 
in Taiz, Dhamar, and Hodeidah governorates in western 
Yemen [11]. Pfdhfr mutant allele (N108) was also reported 
in 53.2 % of P. falciparum isolates collected from Hodei-
dah governorate [12]. However, data on Pfdhfr and 
Pfdhps mutant alleles and genotypes are not available 
from the southeastern governorates of Yemen. This study 
aimed to screen Pfdhfr and Pfdhps mutant alleles and 
genotypes among P. falciparum population isolated from 
a community-based survey conducted in Hadhramout. 
Findings from this study will be used to predict the devel-
opment of SP resistance.
Methods
Study sites/subjects and sampling
Blood samples were collected from two districts in 
Hadhramout governorate (Hajer and Al-Raydah–Qusyer 
districts) in southeastern Yemen, representing about 
36 % of the total area of Yemen with an estimated popu-
lation of 1,028,556 [13]. Hadhramout has a humid and 
hot climate which is characterized by humidity levels 
ranging from 18 to 93 % and temperature ranging from 
18 to 38 °C. Malaria is endemic in Hajer and Al-Raydah–
Qusyer districts with more than 99 % of cases caused by 
P. falciparum and few cases of Plasmodium vivax [2]. 
House-to-house survey was conducted during the trans-
mission season from July 2011 to May 2012. Finger-prick 
blood samples were collected from 735 participants in 
three villages in Hajer and four villages in Al-Raydah–
Qusyer districts (Fig.  1). These villages were selected 
because they are endemic malaria areas, and houses 
were selected randomly. Informed consent was obtained 
from each participant, and consent was obtained from 
the parents of children after the survey objectives were 
clearly explained to the subjects. The Faculty of Medi-
cine, Hadhramout University for Science and Technol-
ogy, and the Ministry of Health and Population, Yemen 
approved the study protocol. Malaria positive patients 
were treated by NMCP following the national anti-
malarial drug policy.
addition, monitoring SP efficacy using molecular markers that has shown to be a practical and informative method for 
monitoring the partner drug of AS.
Keywords: Plasmodium falciparum, Pfdhfr, Pfdhps, Sulphadoxine–pyrimethamine resistance, Molecular marker, 
Hadhramout-Yemen
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Detection of Pfdhfr and Pfdhps mutations
Archive blood spots were collected on Whatman filter 
paper 3MM (Whatman International Ltd., Maidstone, 
England) and maintained separately in clean, dry, and 
well-sealed plastic bag with silica gel. The bags were 
stored at room temperature until use. Genomic DNA 
was extracted from dried archive blood spots using 
Qiagen DNA Mini Kit for blood and tissue (QIAGEN, 
Germany) according to the manufacturer’s instruc-
tions. Extracted DNA was eluted using 50 µL of Qiagen 
AE elution buffer and stored at −20  °C until use. Plas-
modium falciparum was identified using nested PCR 
based on small subunit ribosomal RNA gene [14, 15]. 
PCR master mix and thermal cycling conditions were 
performed as reported previously [16]. Genomic DNA 
of Pfdhfr gene was amplified using nested PCR follow-
ing the method described previously [17, 18]. Briefly, an 
amplicon of 720 bp was amplified using the primers pair 
AMPI (5′-TTTATATTTTCTCCTTTTTA-3′) and AMP2 
(5′-CATTTTATTATTCGTTTTCT-3′) in the primary 
PCR, and an amplicon of 700 bp was amplified using the 
primers SP1 (5′-ATGATGGAACAAGTCTGCGAC-3′) 
and SP2 (5′-ACATTTTATTATTCGTTTTC-3′) in the 
nested PCR. The PCR was carried out in a total of 25 μl 
mixture containing 1× PCR buffer, 3 mM MgCl2, 0.2 mM 
of dNTPs, 200 nM of each primer, 1 U of Taq polymer-
ase and 4 μl of genomic DNA. Cycling condition was as 
follows; initial denaturation at 94 °C for 3 min, followed 
by 45 cycles of denaturing for 30  s at 94  °C, annealing 
for 1 min at 43.5 °C and extension at 72 °C for 45 s, and 
final extension at 72 °C for 5 min. The cycling condition 
for nested PCR was the same except that annealing was 
at 55 °C for 45 s and extension at 74 °C for 35 s, besides 
decreasing the number of cycles to 35 cycles.
An amplicon of 711  bp of Pfdhps gene was ampli-
fied by nested PCR using the outer primers pair; O1 
(5′-GATTCTTTTTCAGATGGAGG-3′) and O2 (5′-TT 
CCTCATGTAATTCATCTGA-3′), and the nested prim-
ers; N1 (5′-AACCTAAACGTGCTGTTCAA-3′) and 
N2: (5′-AATTGTGTGATTTGTCCACAA-3′) [19]. The 
PCR mixture was as described above. The cycling condi-
tion for primary and secondary PCR was as follows; ini-
tial denaturation at 94 °C for 3 min followed by 25 cycles 
of denaturing for 1 min at 94 °C, annealing for 2 min at 
52  °C and extension at 74  °C for 1 min and final exten-
sion at 74 °C for 5 min. PCR reagents and primers were 
obtained from iNtRON (iNtRON Biotechnology, Inc., 
Seoul, Republic of Korea. PCR product was analysed by 
Fig. 1 Map indicates the study area [56]
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electrophoresis in a 2.5 % agarose gel containing SYBER® 
safe DNA gel stain (Invitrogen, USA) and visualized in a 
UV transilluminator. PCR products were purified with 
Presto™ 96 Well PCR Cleanup Kits and then sequenced 
in both directions using the inner primers in the ABI 
3730xl DNA analyzer (Applied Biosystems). Mutations 
were detected by creating consensus sequences and com-
paring manually with the sequences in GenBank (Gen-
Bank accession numbers were XM_001351443 for pfdhfr 
and Z31584 for pfdhps) using BioEdit software [20].
Statistical analysis
Data were analysed using the Statistical Package for 
Social Sciences (SPSS) version 22 (SPSS Inc., Chicago, 
IL, USA). The prevalence of a mutant allele or genotype 
was calculated as the percentage of the presence of the 
mutant allele or the genotype in the examined P. falci-
parum isolates. The difference between proportions was 
examined using Pearson Chi Square test or Fisher’s exact 
test wherever applicable. P value <0.05 was considered 
significant.
Results
A total of 137 patients infected with P. falciparum based 
on microscopic examination of blood smear and nested 
PCR were included in the analysis of Pfdhfr mutations at 
codons 51, 59, 108, and 164, as well as Pfdhps mutations 
at codons 436, 437, and 540. The majority of patients 
(57.7 %) were aged >15 years old, and 88 % (121/137) of 
the patients did not use mosquito bed nets. 52 % (71/137) 
of the patients had no fever during the survey. The mean 
of hemoglobin was 9.5 ± 1 g/dl. The median of parasite 
densities was 960 asexual parasite/µl with interquar-
tile range of 560–2333 asexual parasite/µl. The sex ratio 
was 1.7 males/females. Of the 137 P. falciparum isolates, 
genomic DNAs from 128 and 114 isolates were success-
fully sequenced for Pfdhfr and Pdhps genes, respectively.
Mutant alleles are presented in Table  1. Pfdhfr muta-
tions were detected in 84  % (107/128) of P. falciparum 
isolates for codons 51 (I51) and 108 (N108) and in one 
isolate for codon 59 (R59). Mutation was not identified 
at codon 164. A single mutation in codon 437 (G437) in 
the Pfdhps gene was detected in 44.7 % (51/114) isolates. 
No significant difference in the distribution of the mutant 
alleles between Hajer and Al-Raydah–Qusyer districts 
was observed.
Genotyping analysis based on sequences for Pfdhfr, 
Pfdhps, and combined Pfdhfr–Pfdhps genes was con-
ducted. Double (I51C59N108I164) and triple (I51R59N10
8I164) mutant genotypes of Pfdhfr were detected in 82.8 % 
(106/128) isolates and one isolate (0.8  %), respectively. 
For Pfdhps, single mutant genotype (S436G437K540) was 
detected in 44.7  % (51/114) of the isolates. Genotyp-
ing of 106 P. falciparum isolates for the combined Pfd-
hfr–Pfdhps genes showed that five (4.7 %), 46 (43 %), 42 
(39.3 %), and one (0.9) isolates had single, double, triple, 
and quadruple mutant genotypes, respectively. Although 
Al-Raydah–Qusyer district had higher prevalence of 
mutant genotypes than Hajer district, the differences 
were statistically not significant (Table 2).
Table 1 Prevalence of mutant alleles of pfdhfr and pfdhps in P. falciparum isolates from Hadhramout, Yemen
n sample size, NA not applicable
a Mutant alleles are bold and underlined
b The difference was examined using Fisher exact test








 51I 19 (73.1) 88 (86.3) 107 (84) 0.105
 59R 0 (00) 1 (1.0) 1 (0.8) 0.797b
 108N 19 (73.1) 88 (86.3) 107 (84) 0.105
 164L 0 (00) 0 (00) 0 (00) NA








 436A 0 (00) 0 (00) 0 (00) NA
 437G 9 (36) 42 (47) 51 (44.7) 0.56
 540E 0 (00) 0 (00) 0 (00) NA
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Discussion
This study was conducted to investigate mutations in 
Pfdhfr and Pfdhps genes as predictors of resistance of 
SP anti-malarial treatment. High prevalence (84  %) of 
Pfdhfr mutant alleles I51 and N108 was found among 
P. falciparum population in Hadhramout. These find-
ings were higher than those from previous reports from 
western governorates of Yemen [11, 12]. Pfdhfr mutant 
allele R59 was detected in one isolate of P. falciparum 
in this study. However, a study conducted in Lahj gov-
ernorate reported four samples harboring this mutant 
allele in 99 P. falciparum isolates [10]. Mutation at codon 
437 of Pfdhps (G437) was also detected for the first time 
in 44.7  % of the examined isolates. Increased frequency 
of mutant alleles of Pfdhfr gene and emergence of new 
mutant alleles of Pfdhps gene in Yemen are early alarm-
ing signals of the possibility of decreasing in the efficacy 
of SP. Accumulation of mutations in Pfdhfr gene starts 
at codon 108 from serine to asparagine, resulting in low 
levels of pyrimethamine resistance followed by mutations 
I51 and R59, as well as at codon L164 point mutation which 
is related to high level of resistance [21]. Similarly, sulf-
adoxine resistance is induced by mutations in the Pdhps 
gene at codons 436, 437, 540, 581, and 613, that starts ini-
tially with mutation at codon 437 from alanine to glycine, 
followed by E540 and G581, as well as other mutations 
[22–24]. Emergence of resistant parasite to anti-malarial 
drugs involves many factors, such as economic effects, 
human hosts, drug pattern interactions, characteristics of 
the drug itself, parasites, vectors, and environmental fac-
tors [25–29].
Drug pressure could have driven the emergence and 
spreading of the mutant genotypes in this study. SP had 
been used as the second-line monotherapy for treating 
uncomplicated malaria for approximately more than 5 
years before the introduction of ACT drug policy in 2005 
[3, 5], which theoretically terminated the use of SP mono-
therapy. Moreover, SP is not used for intermittent preven-
tive treatment in pregnant women in Yemen. However, SP 
is still available in the private sector where private physi-
cians have poorer knowledge about the new drug policy 
[7, 30] emphasizing the possibility of continued use of SP 
Table 2 Prevalence of  genotypes of  pfdhfr, pfdhps, and  combined pfdhfr–pfdhps genes in  P. falciparum isolates 
from Hadhramout, Yemen
n sample size, NA not applicable
a Mutant alleles are bold and underlined
b The difference was examined using Fisher exact test








 N51C59S108I164 7 (26.9) 14 (13.7) 21 (17) 0.105
 I51C59N108I164 19 (73.1) 87 (85.3) 106 (82.8) 0.140
 I51R59N108I164 0 (0) 1 (1) 1 (0.8) 0.797
b








S436A437K540 16 (64) 47 (52.8) 63 (55.3)
 S436G437K540 9 (36) 42 (47.2) 51 (44.7) 0.56








 N51C59S108I164-S436A437K540 5 (20) 8 (9.8) 13 (12.1) 0.170
 N51C59S108I164-S436G437K540 1 (4) 4 (4.8) 5 (4.7) 1.000
b
 I51C59N108I164-S436A437K540 11 (44) 35 (42.7) 46 (43) 0.907
 I51C59N108I164-S436G437K540 8 (32) 34 (41.5) 42 (39.3) 0.396
 I51R59N108I164-S436G437K540 0 (00) 1 (1.2) 1 (0.9) 1.000
b
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monotherapy, which may result in the development of SP 
resistance [31]. Another possible reason could be the inten-
sity of transmission; Hadhramout has been classified as low 
malaria transmission area and the initiation of pre-elimina-
tion phase was suggested [3]. The development and spread-
ing of anti-malarial drug resistance in low transmission 
area has been well documented [32]. Most patients in low 
transmission area are usually symptomatic and receive anti-
malarial treatment, which increases the chance of selecting 
the resistant parasite. Nevertheless, this classification is not 
supported by recent studies that have reported high preva-
lence of malaria in the community setting [2] and among 
asymptomatic blood donors in Hadhramout [33].
The present study showed high frequency of double 
mutant genotype (I51C59N108I164) among P. falciparum iso-
lates. This genotype has been reported in Sudan [34, 35], 
Saudi Arabia [36], Angola [37], Uganda [38], Gabon [39], 
Iran [40] and Afghanistan [41]. In vitro studies showed a 
strong association between the Pfdhfr double mutant (I51 
and N108) and pyrimethamine resistance in Kolkata, West 
Bengal of India, and Purulia [42, 43]. Another study con-
ducted among Colombian children indicated that dou-
ble mutant (I51 and N108) is significantly associated with 
delayed parasite clearance and plays a role in gametogen-
esis [44]. By contrast, a study in Sudan reported that the 
presence of Pfdhfr double mutant I51 and N108 alone is 
insufficient to induce in vivo resistance [45]. In this study, 
Pfdhfr triple mutant genotype (I51R59N108) was detected in 
one P. falciparum isolate. This genotype has been strongly 
associated with in  vitro and in  vivo SP resistance [46]. 
Mutant genotype (I51C59N108I164-S436G437K540), which com-
bined Pfdhfr double mutants (I51, N108) and Pfdhps single 
mutant (G437), was highly prevalent among P. falciparum 
isolates. Lower frequencies of this mutant genotype com-
pared with the present study have been reported from 
southeastern Iran at 2.7 % during 2008–2005 [40] and again 
at 1.8 % during 2008–2010 [47], as well as in Tanzania at 
0.1 % [48]. Literature review showed that this genotype is 
not widely distributed and has not been correlated yet with 
the efficacy of SP either in vitro or in vivo. In this study, one 
isolate of P. falciparum harboured quadruple mutant geno-
type combining the triple Pdhfr mutant (I51R59N108) and 
single Pdhps mutant G437. Significant association between 
SP resistance and this genotype has been reported from 
in vivo studies conducted in Mali and Ghana only after 1 
year of implementation of intermittent preventive treat-
ment of malaria in infant [49, 50]. Low occurrence of this 
genotype has been reported from Northern Benin [51], 
contrary to the high prevalence reported from Southern 
Benin [52], Ethiopia, [53], and Senegal [54].
Anti-malarial drug policy has been designed to combine 
AS with longer half-live partner drug which clears the 
remaining parasite and prevent or delay the emergence of 
resistance to AS [55]. In Yemen, SP has been the partner 
drug combined with AS for treating uncomplicated falci-
parum malaria [3] therefore the emergence of SP resist-
ance will expose the parasite to AS monotherapy, which 
has the potential to contribute to the emergence of ACT 
resistance in this country. In 2004, three in  vivo clinical 
efficacy trails showed that SP monotherapy was highly 
efficacies for treating falciparum malaria [3]. From the 
time when anti-malarial drug policy had shifted from SP 
monotherapy as second-line to AS +  SP as first-line for 
treating uncomplicated malaria, all in  vivo efficacy tri-
als have assessed the drug combination (AS + SP) as still 
being effective [8]. However, the inability of the routine 
therapeutic trails to distinguish between the efficacy of 
AS and its partner drug put SP efficacy under uncertainty 
particularly with the high prevalence of the double mutant 
genotype, which has good correlation with decreasing SP 
efficacy [43, 44]. In contrast, the non-emergence of quad-
ruple Pdhfr mutant and triple Pdhps mutant genotypes 
that have been associated with the severe failure of SP [9] 
indicates that SP still provides good therapeutic response.
Conclusion
The present study reported high prevalence of Pfdhfr 
double mutant genotype (I51R59N108) and triple Pfdhfr-
Pfdhps mutant genotype (I51C59N108I164-S436G437K540) in 
P. falciparum population in Hadhramout, Yemen. These 
results highlight the risk of developing resistance for SP, 
the partner drug of AS, which subsequently will expose 
the parasite to AS monotherapy increasing the potential 
of the emergence of AS resistance in Yemen. Study find-
ings necessitate continuous monitoring of the efficacy of 
the national anti-malarial drug policy in Yemen using the 
in vivo efficacy trails. In addition, monitoring the SP effi-
cacy using molecular markers is crucial for early alarm-
ing of the risk of emerging AS resistance.
Authors’ contributions
MAKM and YALL planned and designed the protocols. OAAB conducted the 
field study and the study programme, including blood sample collection 
and data from the questionnaire, interviews, as well as the management of 
collecting data. MAKM and YALL supervised all the laboratory work. All authors 
carried out the data analysis and interpretation. All authors prepared the first 
draft of the manuscript and revised the manuscript critically. All authors read 
and approved the final manuscript.
Author details
1 Department of Parasitology, Faculty of Medicine, University of Malaya, 
50603 Kuala Lumpur, Malaysia. 2 Department of Parasitology, Faculty of Medi-
cine, Sana’a University, Sana’a, Yemen. 3 Tropical Disease Research Center, 
University of Science and Technology, Sana’a, Yemen. 
Acknowledgements
The authors thank all the technical staff in the field of study and laboratory 
expert group for their assistance in the laboratory work, the Malaria National 
Control Programme in Hadhramout governorate-Yemen, Ministry of Health 
and Population in Hadhramout for their cooperation during this study. We 
also gratefully acknowledge Dr. Georges Snounou who provided constructive 
comments for this manuscript.
Page 7 of 8Bamaga et al. Malar J  (2015) 14:516 
Competing interests
The authors declare that they have no competing interests.
Financial support
The study was funded by the University of Malaya Research Grant (UMRG-
RG503-13HTM). The funder had no role in study design, data collection and 
analysis, decision to publish or preparation of the manuscript.
Received: 21 October 2015   Accepted: 4 December 2015
References
 1. World Health Organization. World malaria report. Geneva; 2014.
 2. Bamaga OA, Mahdy MA, Mahmud R, Lim YA. Malaria in Hadhramout, 
a southeast province of Yemen: prevalence, risk factors, knowledge, 
attitude and practices (KAPs). Parasit Vectors. 2014;7:351.
 3. NMCP. Yemen’s national malaria control and elimination strategic plan 
2011–2015. Ministry and Public Health and Population, primary Health 
Care Sector, National Malaria Control Programme. 2011.
 4. World Health Organization. World malaria report. Geneva; 2012.
 5. NMCP. Yemen’s national malaria control and elimination strategic plan 
2006–2010. Ministry and Public Health and Population, primary Health 
Care Sector, National Malaria Control Programme. 2006.
 6. World Health Organization. World malaria report. Geneva; 2011.
 7. Bin Ghouth AS. Availability and prescription practice of anti-malaria drugs 
in the private health sector in Yemen. J Infect Dev Ctries. 2013;7:404–12.
 8. Adeel AA, Saeed NA, Aljasari A, Almohager AM, Galab MH, AlMahdi 
A, et al. High efficacy of two artemisinin-based combinations: artesu-
nate + sulfadoxine–pyrimethamine and artemether–lumefantrine for 
falciparum malaria in Yemen. Malar J. 2015;14:449.
 9. Picot S, Olliaro P, de Monbrison F, Bienvenu A-L, Price RN, Ringwald P. A 
systematic review and meta-analysis of evidence for correlation between 
molecular markers of parasite resistance and treatment outcome in 
falciparum malaria. Malar J. 2009;8:89.
 10. Mubjer RA, Adeel AA, Chance ML, Hassan AA. Molecular markers of anti-
malarial drug resistance in Lahj Governorate, Yemen: baseline data and 
implications. Malar J. 2011;10:245.
 11. Al-Hamidhi S, Mahdy MA, Al-Hashami Z, Al-Farsi H, Al-Mekhlafi AM, Idris 
MA, et al. Genetic diversity of Plasmodium falciparum and distribution of 
drug resistance haplotypes in Yemen. Malar J. 2013;12:244.
 12. Abdul-Ghani R, Farag HF, Allam AF, Shawky SM. Prevailing Plasmodium fal-
ciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: a 
questionable sulfadoxine–pyrimethamine partner within the artemisinin-
based combination therapy. Acta Trop. 2014;132:39–44.
 13. CSO. Statistical report of Yemen. The Central Statistical Organization. 
Ministry of Planning and International Cooperation, Yemen. 2013.
 14. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman 
HA. A genus- and species-specific nested polymerase chain reaction 
malaria detection assay for epidemiologic studies. Am J Trop Med Hyg. 
1999;60:687–92.
 15. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identifica-
tion of the four human malaria parasite species in field samples by the 
polymerase chain reaction and detection of a high prevalence of mixed 
infections. Mol Biochem Parasitol. 1993;58:283–92.
 16. Snounou G. Detection and identification of the four malaria parasite 
species infecting humans by PCR amplification. Methods Mol Biol. 
1996;50:263–91.
 17. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine 
and proguanil resistance-conferring mutations in Plasmodium falciparum 
dihydrofolate reductase: polymerase chain reaction methods for surveil-
lance in Africa. Am J Trop Med Hyg. 1995;52:565–8.
 18. Tinto H, Ouedraogo JB, Zongo I, van Overmeir C, van Marck E, Guig-
uemde TR, et al. Sulfadoxine–pyrimethamine efficacy and selection 
of Plasmodium falciparum DHFR mutations in Burkina Faso before its 
introduction as intermittent preventive treatment for pregnant women. 
Am J Trop Med Hyg. 2007;76:608–13.
 19. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecu-
lar determination of point mutation haplotypes in the dihydrofolate 
reductase and dihydropteroate synthase of Plasmodium falciparum in 
three districts of northern Tanzania. Antimicrob Agents Chemother. 
2003;47:1347–54.
 20. Hall T. BioEdit: an important software for molecular biology. GERF Bull 
Biosci. 2011;2:60–1.
 21. Hyde JE. The dihydrofolate reductase-thymidylate synthetase gene 
in the drug resistance of malaria parasites. Pharmacol Therapeut. 
1990;48:45–59.
 22. Cowman AF, Morry MJ, Biggs BA, Cross G, Foote SJ. Amino acid changes 
linked to pyrimethamine resistance in the dihydrofolate reductase-thymi-
dylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 
1988;85:9109–13.
 23. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to 
antifolates. Pharmacol Rev. 2005;57:117–45.
 24. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. 
Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what 
next? Trends Parasitol. 2001;17:570–1.
 25. Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmo-
dium falciparum. Pharmacol Therapeut. 1991;50:95–121.
 26. Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, 
Pang L. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian 
borders. Southeast Asian J Trop Med Public Health. 2001;32:41–9.
 27. Winstanley P. Modern chemotherapeutic options for malaria. Lancet 
Infect Dis. 2001;1:242–50.
 28. Molyneux D, Floyd K, Barnish G, Fevre E. Transmission control and drug 
resistance in malaria: a crucial interaction. Parasitol Today. 1999;15:238–40.
 29. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Trop. 
1994;56:143–56.
 30. Bashrahil KA, Bingouth AS, Baruzaig AS. Antimalarial drugs: availability 
and mode of prescribing in Mukalla, Yemen. East Mediterr Health J. 
2010;16:146–50.
 31. Alexander N, Sutherland C, Roper C, Cisse B, Schellenberg D. Modelling 
the impact of intermittent preventive treatment for malaria on selection 
pressure for drug resistance. Malar J. 2007;6:9.
 32. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental 
spread of pyrimethamine-resistant malaria. Science. 2004;305:1124.
 33. Othman RA, Eldeek HE, Almatary AM, Sayed AA, Alsakaf A. Detection of 
malaria in healthy blood donors using PCR in an endemic area in Yemen. 
J Adv Parasitol. 2015;2:40–7.
 34. A-Elbasit I, Khalil I, Elbashir M, Masuadi E, Bygbjerg I, Alifrangis M, et al. 
High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplo-
types without association with resistance to sulfadoxine/pyrimethamine 
and chloroquine combination in the Daraweesh area, in Sudan. Eur J Clin 
Microbiol Infect Dis. 2008;27:725–32.
 35. Al-Saai S, Kheir A, Abdel-Muhsin A-MA, Al-Ghazali A, Nwakanma 
D, Swedberg G, et al. Distinct haplotypes of dhfr and dhps among 
Plasmodium falciparum isolates in an area of high level of sulfadox-
ine–pyrimethamine (SP) resistance in eastern Sudan. Infect Genet Evol. 
2009;9:778–83.
 36. Al-Farsi HM, Al-Hashami ZS, Dajem SMB, Al-Sheikh AAH, Al-Qahtani A, 
Beja-Pereira A, et al. Source of drug resistant Plasmodium falciparum in 
a potential malaria elimination site in Saudi Arabia. Infect Genet Evol. 
2012;12:1253–9.
 37. Menegon M, Pearce RJ, Inojosa WO, Pisani V, Abel PM, Matondo A, et al. 
Monitoring for multidrug-resistant Plasmodium falciparum isolates and 
analysis of pyrimethamine resistance evolution in Uige province, Angola. 
Trop Med Int Health. 2009;14:1251–7.
 38. Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, Pet-
tersson M, et al. Rapid increase in resistance of Plasmodium falciparum 
to chloroquine-Fansidar in Uganda and the potential of amodiaquine-
Fansidar as a better alternative. Acta Trop. 2005;95:172–82.
 39. Bouyou-Akotet MK, Mawili-Mboumba DP, de Dieu Tchantchou T, Kombila 
M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of 
Plasmodium falciparum isolates in pregnant women at the time of intro-
duction of intermittent preventive treatment with sulfadoxine/pyrimeth-
amine in Gabon. J Antimicrob Chemother. 2010;65:438–41.
 40. Zakeri S, Farahani MS, Afsharpad M, Salehi M, Raeisi A, Djadid ND. High 
prevalence of the 437G mutation associated with sulfadoxine resistance 
among Plasmodium falciparum clinical isolates from Iran, three years 
after the introduction of sulfadoxine–pyrimethamine. Int J Infect Dis. 
2010;14:e123–8.
Page 8 of 8Bamaga et al. Malar J  (2015) 14:516 
 41. Awab GR, Pukrittayakamee S, Jamornthanyawat N, Yamin F, Dondorp AM, 
Day NP, et al. Prevalence of antifolate resistance mutations in Plasmodium 
falciparum isolates in Afghanistan. Malar J. 2013;12:96.
 42. Das S, Chakraborty SP, Tripathy S, Hati AK, Roy S. Association between 
prevalence of pyrimethamine resistance and double mutation in pfdhfr 
gene in West Bengal, India. Asian Pac J Trop Dis. 2012;2:31–5.
 43. Das S, Chakraborty SP, Hati A, Roy S. Malaria treatment failure with 
novel mutation in the Plasmodium falciparum dihydrofolate reductase 
(pfdhfr) gene in Kolkata, West Bengal, India. Int J Antimicrob Agents. 
2013;41:447–51.
 44. Mendez F, Munoz A, Carrasquilla G, Jurado D, Arevalo-Herrera M, Cortese 
JF, et al. Determinants of treatment response to sulfadoxine–pyrimeth-
amine and subsequent transmission potential in falciparum malaria. Am J 
Epidemiol. 2002;156:230–8.
 45. Khalil I, Alifrangis M, Rønn AM, Gabar HA, Jelinek T, Satti GM, et al. 
Pyrimethamine/sulfadoxine combination in the treatment of uncompli-
cated falciparum malaria: relation between dihydropteroate synthase/
dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treat-
ment outcome. Am J Trop Med Hyg. 2002;67:225–9.
 46. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, 
Martino LM, et al. Molecular markers for failure of sulfadoxine–pyrimeth-
amine and chlorproguanil-dapsone treatment of Plasmodium falciparum 
malaria. Int J Infect Dis. 2002;185:380–8.
 47. Rouhani M, Zakeri S, Pirahmadi S, Raeisi A, Djadid ND. High prevalence of 
pfdhfr–pfdhps triple mutations associated with anti-malarial drugs resist-
ance in Plasmodium falciparum isolates seven years after the adoption of 
sulfadoxine–pyrimethamine in combination with artesunate as first-line 
treatment in Iran. Infect Genet Evol. 2015;31:183–9.
 48. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, van Zwetselaar M, 
et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps 
quintuple mutations: a cross sectional survey of six regions in Tanzania. 
Malar J. 2014;13:152.
 49. Dicko A, Sagara I, Djimdé AA, Touré SO, Traore M, Dama S, et al. Molecular 
markers of resistance to sulphadoxine–pyrimethamine one year after 
implementation of intermittent preventive treatment of malaria in infants 
in Mali. Malar J. 2010;9:9.
 50. Mockenhaupt FP, Bousema TJ, Eggelte TA, Schreiber J, Ehrhardt S, Was-
silew N, et al. Plasmodium falciparum dhfr but not dhps mutations associ-
ated with sulphadoxine–pyrimethamine treatment failure and gameto-
cyte carriage in northern Ghana. Trop Med Int Health. 2005;10:901–8.
 51. Ogouyèmi-Hounto A, Ndam NT, Fadégnon G, Azagnandji C, Bello M, 
Moussiliou A, et al. Low prevalence of the molecular markers of Plasmo-
dium falciparum resistance to chloroquine and sulphadoxine/pyrimeth-
amine in asymptomatic children in Northern Benin. Malar J. 2013;12:413.
 52. Ogouyèmi-Hounto A, Ndam NT, Gazard DK, d’Almeida S, Koussihoude 
L, Ollo E, et al. Prevalence of the molecular marker of Plasmodium falci-
parum resistance to chloroquine and sulphadoxine/pyrimethamine in 
Benin seven years after the change of malaria treatment policy. Malar J. 
2013;12:147.
 53. Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González 
V, et al. Detection of high levels of mutations involved in anti-malarial 
drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural 
hospital in southern Ethiopia. Malar J. 2011;10:214.
 54. Ndiaye D, Dieye B, Ndiaye YD, Van Tyne D, Daniels R, Bei AK, et al. Poly-
morphism in dhfr/dhps genes, parasite density and ex vivo response 
to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, 
Senegal. Int J Parasitol Drugs Drug Resist. 2013;3:135–42.
 55. WHO. Guidelines for the treatment of malaria, 3rd edn. World Health 
Organization: Geneva. 2015. http://www.who.int/malaria/publications/
atoz/9789241549127/en/.
 56. Bamaga OA, Mahdy MA, Lim YA. Survey of chloroquine-resistant muta-
tions in the Plasmodium falciparum pfcrt and pfmdr-1 genes in Hadh-
ramout, Yemen. Acta Trop. 2015;149:59–63.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
